{"id":394477,"date":"2020-12-07T10:03:14","date_gmt":"2020-12-07T15:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394477"},"modified":"2020-12-07T10:03:14","modified_gmt":"2020-12-07T15:03:14","slug":"arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/","title":{"rendered":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma"},"content":{"rendered":"
\n

\n – Company announces initial results in<\/em>
\n first<\/em>
\n –<\/em>
\n in<\/em>
\n –<\/em>
\n human trial <\/em>
\n utilizing novel synthetic binding domain<\/em>
\n –<\/em>
\n \n <\/p>\n

\n – <\/em>
\n 6\/6 (100%) overall response rate<\/em>
\n (ORR)<\/em>
\n per <\/em>
\n International Myeloma Working Group <\/em>
\n (<\/em>
\n IMWG<\/em>
\n )<\/em>
\n criteria<\/em>
\n observed at Dose Level 1<\/em>
\n –<\/em>\n <\/p>\n

GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) — Arcellx, a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced initial clinical data from the first six patients treated in the company\u2019s ongoing Phase 1 Study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA was well tolerated and rapid, deep, and durable responses were observed at the first dose level of 100 million cells, with six of six evaluable patients responding per IMWG criteria. Four of six patients achieved stringent complete responses, two patients achieved a partial response, and all patients are ongoing in the trial. All patients treated were penta-refractory with multiple poor prognostic factors, including high-risk cytogenetics. The initial results were presented today at the 62nd<\/sup> American Society of Hematology (ASH) Annual Meeting.<\/p>\n

\u201cThese initial clinical data suggest the promise of CART-ddBCMA as a BCMA-targeted therapy,\u201d commented Matthew J. Frigault, M.D., study investigator and Assistant Director of the Cellular Therapy Service at Massachusetts General Hospital Cancer Center and Instructor at Harvard Medical School. \u201cThe observations of rapid, durable responses in patients in this difficult-to-treat patient population are highly encouraging. We are eager to see results with additional patients and longer follow-up from this ongoing study.\u201d<\/p>\n

The full presentation is available online on the ASH annual meeting website. The clinical data is available on the Scientific Publications<\/a> section of the Arcellx website at www.arcellx.com<\/a>.<\/p>\n

\n About the Arcellx ddBCMA Cell Therapy Phase 1 Trial <\/strong>\n <\/p>\n

CART-ddBCMA is a Phase 1 study of Arcellx\u2019s BCMA-specific CAR-modified T-cell therapy utilizing the company\u2019s novel BCMA-targeting binding domain for the treatment of patients with relapsed and refractory multiple myeloma. Arcellx\u2019s proprietary binding domains\u2014a central component of Arcellx\u2019s ARC-sparX platform\u2014are novel synthetic proteins engineered for reduced immunogenicity and designed to bind specific therapeutic targets. The Arcellx ddBCMA cell therapy has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration. The Phase 1 study is currently enrolling patients. Additional information about the trial can be found at https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04155749<\/a>.<\/p>\n

\n About Arcellx\u2019s <\/strong>
\n ARC-sparX <\/strong>
\n Platform<\/strong>
\n Technology<\/strong>\n <\/p>\n

The two-part ARC-sparX platform separates the disease recognition and killing functions of conventional cell therapies, enabling a controllable cell therapy that can be adapted to the patient\u2019s disease. First, sparX proteins bind to specific antigens on diseased cells using a novel synthetic binding domain, then flag those cells for destruction by ARC-T cells. Next, ARC-T cells, which cannot recognize diseased cells on their own, bind to sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins with unique binding domains directed at a number of therapeutic targets. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration, which has the potential to improve patient safety.<\/p>\n

\n About Arcellx, Inc.<\/strong>\n <\/p>\n

Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. \u00a0The Arcellx vision is to utilize our novel proprietary platform to bring superior cell therapies to more patients through the care of academic and community practices worldwide. More information can be found at www.arcellx.com<\/a>.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Solebury Trout
Zara Lockshin (media)
Tel: +1 646-378-2960
Email: zlockshin@troutgroup.com<\/a>\u00a0\u00a0<\/p>\n

Alan Lada (investors)
Tel: +1 646-378-2927
Email: alada@troutgroup.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– Company announces initial results in first – in – human trial utilizing novel synthetic binding domain – – 6\/6 (100%) overall response rate (ORR) per International Myeloma Working Group ( IMWG ) criteria observed at Dose Level 1 – GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) — Arcellx, a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced initial clinical data from the first six patients treated in the company\u2019s ongoing Phase 1 Study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA was well tolerated and rapid, … <\/p>\n

Continue reading “Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394477","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Company announces initial results in first – in – human trial utilizing novel synthetic binding domain – – 6\/6 (100%) overall response rate (ORR) per International Myeloma Working Group ( IMWG ) criteria observed at Dose Level 1 – GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) — Arcellx, a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced initial clinical data from the first six patients treated in the company\u2019s ongoing Phase 1 Study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA was well tolerated and rapid, … Continue reading "Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T15:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma\",\"datePublished\":\"2020-12-07T15:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/\"},\"wordCount\":656,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/\",\"name\":\"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=\",\"datePublished\":\"2020-12-07T15:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/","og_locale":"en_US","og_type":"article","og_title":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk","og_description":"– Company announces initial results in first – in – human trial utilizing novel synthetic binding domain – – 6\/6 (100%) overall response rate (ORR) per International Myeloma Working Group ( IMWG ) criteria observed at Dose Level 1 – GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) — Arcellx, a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced initial clinical data from the first six patients treated in the company\u2019s ongoing Phase 1 Study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA was well tolerated and rapid, … Continue reading \"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T15:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma","datePublished":"2020-12-07T15:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/"},"wordCount":656,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/","name":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=","datePublished":"2020-12-07T15:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzIyNSMzODU3MzgxIzIxODk4MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcellx-cart-ddbcma-cell-therapy-demonstrates-deep-and-durable-responses-in-the-treatment-of-relapsed-and-refractory-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394477"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}